STOCK TITAN
  1. Home
  2. News
  3. MCRB

Seres Therapeutics Inc - MCRB STOCK NEWS

Welcome to our dedicated news page for Seres Therapeutics (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seres Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seres Therapeutics's position in the market.

News
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) completes enrollment in SER-155 Phase 1b trial for Allo HSCT patients, aiming to reduce infections and improve outcomes. Clinical data readout expected by end of Q3 2024. Potential to expand microbiome therapeutic franchise into other medically vulnerable patient populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
clinical trial
-
News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) granted 700,000 stock options to Marella Thorell, the new Executive Vice President and Chief Financial Officer. The options are part of the 2022 Employment Inducement Award Plan and have an exercise price of $0.79 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) granted inducement equity grants to a new employee, including stock options and RSUs. The grants cover 6,188 shares of common stock, with options at $0.78 per share and vesting over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.34%
Tags
none
News
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) reported net sales of $10.4 million for Q4 2023 and $19.6 million since the launch of VOWST in June 2023. The company saw significant adoption of VOWST with 2,833 patient enrollment forms received and 2,015 new patient starts. They anticipate releasing SER-155 Phase 1b clinical data in Q3 2024. The CEO highlighted the successful commercialization of VOWST and the positive impact on patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
earnings
-
News
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) will host a conference call to discuss Q4 and full year 2023 results and provide a business update on March 5, 2024. Investors can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences earnings
-
News
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) CEO to participate in a panel discussion at Cowen 44th Annual Health Care Conference. The event will be webcasted and archived for 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
conferences
News
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
Rhea-AI Summary
Seres Therapeutics, Inc. (MCRB) appoints Marella Thorell as CFO, succeeding David Arkowitz. Thorell brings extensive industry experience to drive financial strategy and advance product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
management
-
News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) granted inducement equity grants to a new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units covering 22,500 shares of its common stock. The options have an exercise price of $1.21 per share and will vest over time, in accordance with the terms of the Inducement Plan adopted by the company's board of directors in December 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
News
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
Rhea-AI Summary
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced preliminary net sales of approximately $10.4 million for the fourth quarter of 2023. The company also reported significant adoption of VOWST, the first FDA approved orally administered microbiome therapeutic, with 2,833 patient enrollment forms received and 2,015 new patient starts. Additionally, SER-155 Phase 1b placebo-controlled Cohort 2 data readout is anticipated in the third quarter of 2024. Seres is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company also received US FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
clinical trial
News
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via audio webcast and replay, offering investors valuable insights into the company's future plans and strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock MCRB logo
Seres Therapeutics Inc

Nasdaq:MCRB

MCRB Rankings

#4157 Ranked by Market Cap
#5388 Ranked by Stock Gains
N/A Ranked by Dividends

MCRB Stock Data

98.87M
119.11M
5.68%
59.45%
12.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About MCRB

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.